These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 33275094)

  • 1. Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis.
    Berardicurti O; Ruscitti P; Ursini F; D'Andrea S; Ciaffi J; Meliconi R; Iagnocco A; Cipriani P; Giacomelli R
    Clin Exp Rheumatol; 2020; 38(6):1247-1254. PubMed ID: 33275094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
    Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
    Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of tocilizumab in the treatment of severe acute respiratory syndrome coronavirus-2 pneumonia: A retrospective cohort study.
    Patel A; Shah K; Dharsandiya M; Patel K; Patel T; Patel M; Reljic T; Kumar A
    Indian J Med Microbiol; 2020; 38(1):117-123. PubMed ID: 32719218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Selles P; Zahra H; Kadiane-Oussou NJ; Toko L; Royer PY; Balblanc JC; Gendrin V; Conrozier T;
    Int J Infect Dis; 2020 Oct; 99():491-495. PubMed ID: 32798660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with tocilizumab in severe COVID-19 pneumonia after 80 days of follow-up: A retrospective cohort study.
    Moreno-Pérez O; Andres M; Leon-Ramirez JM; Sánchez-Payá J; Rodríguez JC; Sánchez R; García-Sevila R; Boix V; Gil J; Merino E
    J Autoimmun; 2020 Nov; 114():102523. PubMed ID: 32690352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
    Nakamura H; Miyagi K; Otsuki M; Higure Y; Nishiyama N; Kinjo T; Nakamatsu M; Haranaga S; Tateyama M; Fujita J
    Intern Med; 2020 Nov; 59(22):2945-2949. PubMed ID: 32963155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
    Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.
    Rossotti R; Travi G; Ughi N; Corradin M; Baiguera C; Fumagalli R; Bottiroli M; Mondino M; Merli M; Bellone A; Basile A; Ruggeri R; Colombo F; Moreno M; Pastori S; Perno CF; Tarsia P; Epis OM; Puoti M;
    J Infect; 2020 Oct; 81(4):e11-e17. PubMed ID: 32652164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
    Muhović D; Bojović J; Bulatović A; Vukčević B; Ratković M; Lazović R; Smolović B
    Liver Int; 2020 Aug; 40(8):1901-1905. PubMed ID: 32478465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
    Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
    J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab treatment in COVID-19: A single center experience.
    Luo P; Liu Y; Qiu L; Liu X; Liu D; Li J
    J Med Virol; 2020 Jul; 92(7):814-818. PubMed ID: 32253759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
    Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appropriate use of tocilizumab in COVID-19 infection.
    Keske Ş; Tekin S; Sait B; İrkören P; Kapmaz M; Çimen C; Uğur S; Çelebi İ; Bakır VO; Palaoğlu E; Şentürk E; Çağlayan B; Çakar N; Tabak L; Ergönül Ö
    Int J Infect Dis; 2020 Oct; 99():338-343. PubMed ID: 32726724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial and harmful outcomes of tocilizumab in severe COVID-19: A systematic review and meta-analysis.
    Rubio-Rivas M; Forero CG; Mora-Luján JM; Montero A; Formiga F; Homs NA; Albà-Albalate J; Sánchez L; Rello J; Corbella X
    Pharmacotherapy; 2021 Nov; 41(11):884-906. PubMed ID: 34558742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.